Multidrug resistance in haematological malignancies
Article first published online: 28 JUN 2008
Journal of Internal Medicine
Volume 247, Issue 5, pages 521–534, May 2000
How to Cite
Sonneveld, P. (2000), Multidrug resistance in haematological malignancies. Journal of Internal Medicine, 247: 521–534. doi: 10.1046/j.1365-2796.2000.00689.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- acute myeloid leukaemia;
- multiple myeloma;
- multidrug resistance;
- PSC 833
Abstract. Sonneveld P (University Hospital Rotterdam – Dijkzigt, The Netherlands). Multidrug resistance in haematological malignancies (Internal Medicine in the 21st Century). J Intern Med 2000; 247: 521–534.
The development of refractory disease in acute myeloid or lymphoblastic leukaemias (AML, ALL) and multiple myeloma (MM) is frequently associated with the expression of one or several multidrug resistance (MDR) genes. MDR1, MRP1 and LRP have been identified as important adverse prognostic factors in AML, T-ALL and MM. Recently, it has become possible to reverse clinical multidrug resistance by blocking P-glycoprotein-mediated drug efflux. The potential relevance of these reversal agents of MDR and potential new approaches to treat refractory disease are discussed.